Daily Market Updates: The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.

S&P 5007,623.68▼0.5% Nasdaq25,955.34▼0.2% Dow52,215.16▼1.2% Russell 2K2,775.90▼0.3% 10-Yr4.99%+4bp VIX19.45+0.42 WTI$103.44▲4.0% Gold$4,010.00▼1.2% EUR/USD1.120▼0.3% BTC$80,469▼0.8% Nikkei62,908▼2.6%

At close · Sat, Oct 24, 2026

ETFs & Funds

Home›ETFs & Funds›Equity Funds›The real test for Moderna’s cancer vaccine isn’t about…

The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.

Reported · Written up by our desk · Equity Funds

The first Phase 3 data for a cancer vaccine has raised questions about whether the potential new treatment is needed.

← Newer storyMusk's SpaceX is still restricting Starlink in Ukraine and the toll i…Older story →American Express is cutting 5% of its workforce to 'prepare for AI'

More like this

ETFs & FundsEveryone’s talking about Roth conversions, but here’s how few people really do them , and why you shouldn’t have FOMO about it

ETFs & FundsYoung Americans are giving up on car ownership. It’s a path to financial freedom for some.

ETFs & FundsInvestors’ recent money moves show a preference for lowering risks over boosting rewards

ETFs & FundsMy niece’s college rent is covered by a 529 plan. What else can I pay for tax-free?

ETFs & FundsThree Days Inside Quantum World Congress

Sources

MarketWatchThe real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.

MarketWatchThe real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.